HYPERION DEFI, INC. (HYPD) Debt Components
- 2026-06-30: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Notes PayableUSD $8.44M; Debt Instrument, Unamortized Discount, CurrentUSD $92.44K.
- 2026-03-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Notes PayableUSD $8.47M; Debt Instrument, Unamortized Discount, CurrentUSD $36.97K.
- 2025-12-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Notes PayableUSD $7.80M; Debt Instrument, Unamortized Discount, CurrentUSD (m).
- 2025-12-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD $8.34M; Notes PayableUSD (m); Debt Instrument, Unamortized Discount, CurrentUSD $543.23K.
HYPERION DEFI, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Notes Payable, Current USD | Notes Payable USD | Debt Instrument, Unamortized Discount, Current USD | Debt Instrument, Unamortized Discount, Noncurrent USD | Debt Instrument, Unamortized Discount USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Periodic Payment USD | Debt Instrument, Annual Principal Payment USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $8.44M | $92.44K | $339.87K | $432.31K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $8.47M | $36.97K | $450.80K | $487.77K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $7.80M | (m) | $543.25K | $543.25K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.34M | (m) | $543.23K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $8.25M | (m) | $598.69K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.17M | (m) | $654.15K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $9.28M | $10.79M | (m) | $780.68K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $4.74M | $10.74M | (m) | $791.80K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $3.26M | $10.06M | (m) | $635.18K | $163.05K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $815.22K | $10.26M | (m) | $710.68K | $271.75K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $8.78M | (m) | $621.71K | $544.93K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $5.83M | (m) | $503.91K | $846.94K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $3.33M | (m) | $327.22K | $1.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.04M | (m) | $91.62K | $1.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $709.85K | $2.18M | $10.93M | $246.96K | $1.30M | $1.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $174.45K | $416.67K | (m) | $67.77K | $1.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $10.43M | (m) | (m) | $1.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-11-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $7.50M |
| 2022-06-30 | (m) | (m) | $7.73M | (m) | (m) | $297.20K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $8.06M | (m) | (m) | $323.42K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $7.50M | (m) | (m) | $349.63K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $7.28M | $7.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $959.76K | $7.95M | (m) | (m) | (m) | $7.50M | $1.46M | $2.50M | $2.50M | $1.04M | $0.00 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $783.82K | $1.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $463.35K | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $97.54K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $145.94K | $570.28K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $421.60K | $729.25K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-02-24 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $475.22K | 4.29% | $53.75K | (m) |
| 2019-12-31 | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |